BeOne Medicines AG

Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.

BeOne Medicines AG trades at $331, in a confirmed uptrend and 2 weeks into that stage. That is +5.2% against its own 200-day average. It sits at 65% of a 52-week range of $264 to $366. On relative strength it has been ahead of the S&P 500 on a trailing-13-week view for 2 straight weeks.

Today the stock is in a confirmed uptrend — week 2 of stage 2. At $331 it trades +5.2% versus its 200-day average and sits at 65% of its 52-week range ($264–$366).

Against the market, two honest reads. Cumulative: over the last 10.1 years the stock moved +1,033% while the S&P 500 moved +248% — ahead of the index over the full window. Recent form: on a trailing-13-week view the stock has been ahead for 2 straight weeks — the ribbon below is that same metric, week by week.

What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.

→ The trend is one thing; the bill is another. Are you paying up for it? Next: how the P/E reads against its own history.

Valuation P/E is the price of $1 of annual profit: how many dollars the market pays for each dollar the company earns in a year.

BeOne Medicines AG trades at 75.0× P/E, against too little history to rank. This places the multiple against the stock’s own record, and says nothing about what the business is worth.

Today's P/E of 75.0× is against too little history to rank. This is a comparison against the stock's own history — not a claim about what it is worth.

Put together: the multiple is unremarkable against its own past, so the story rests on the earnings line underneath it, not the multiple.

→ Cheap or dear rides on the earnings. Are they actually growing? Next: the fundamental stage — where the business sits in its arc, and how growth has compounded.

Stage: No read Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).

BeOne Medicines AG reads as no read on its fundamental arc. Under eight usable quarters on the growth trio — not enough history for an honest trajectory read. The read is built from 12 quarters across 2 curves, on partial evidence.

Why it matters: with too little history, an honest page says so instead of guessing a trajectory.

One or more growth curves carry a base-effect spike — a large year-on-year move off a near-zero or loss-making comparable quarter. Those spikes are capped before the classifier reads the trajectory, and shown pinned on the chart, so a single distorted quarter does not drive the stage call.

Fewer than eight usable quarters on the growth curves — this page will not guess a trajectory from a stub of history.

→ The stage names the trajectory. Next: the revenue line that produces it, quarter by quarter.

4-Factor Sector Score

50.6/100 — rank 10 of 30 in Biotechnology · 65% evidence confidence

BeOne Medicines AG scores 50.6 out of 100 against the 30 companies it is compared with in Biotechnology, ranking 10. Acceleration candidate, not a confirmed leader: earnings are strong but sector-relative strength is -18.7% and the one-year return is 10.5%. Do not upgrade until sector-relative strength is above zero and another reported period confirms growth.

The four contributions add to the total exactly: 22.9 + 11.9 + 9.1 + 6.7 = 50.6. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.

What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.

Revenue Revenue is the top line: everything the company billed its customers in the period.

BeOne Medicines AG reported $1.5 B of revenue in the Mar 26 quarter, +34.8% year on year. That is the 12th straight quarter of year-on-year growth. Over 4 years it has compounded at 45.9% a year. The last full year, FY25, came in at $5.3 B. The last four reported quarters add to $5.7 B.

BeOne Medicines AG reported $1.5 B of revenue in the Mar 26 quarter, +34.8% year on year. That is the 12th straight quarter of year-on-year growth. Over 4 years it has compounded at 45.9% a year. The last full year, FY25, came in at $5.3 B. The last four reported quarters add to $5.7 B.

FY25 revenue came in at $5.3 B (+40.2% on the year), capping 4 years at 45.9% compound. The latest quarter (Mar 26) printed $1.5 B, +34.8% year on year — the 12th consecutive quarter of year-over-year growth.

Pace check: the last four quarters averaged +37.6% growth against the decade's 45.9% — the current year is running slower than its own long-run rate.

Acceleration check: trailing-twelve-month revenue grew +37.3% over the last 4 quarters against +44.2%/yr over the last 8 — rolling over.

→ Revenue grew — did margins hold as it scaled? Next: 16.6% this quarter (+15.7 pp YoY).

Operating margin Operating margin is what is left of every $100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.

BeOne Medicines AG's operating margin is 16.6% in the Mar 26 quarter, +15.7 percentage points against the same quarter a year ago. That is the widest this company has ever printed on a full-year basis. Across 5 fiscal years the operating margin has ranged −126.1% to 8.4%. The current quarter is running above every full year in that window.

BeOne Medicines AG's operating margin is 16.6% in the Mar 26 quarter, +15.7 percentage points against the same quarter a year ago. That is the widest this company has ever printed on a full-year basis. Across 5 fiscal years the operating margin has ranged −126.1% to 8.4%. The current quarter is running above every full year in that window.

The latest quarter's operating margin is 16.6%, +15.7 pp against the same quarter a year ago. Across 5 fiscal years the operating margin has ranged −126.1%–8.4%, and FY25's 8.4% is the top of that band — a record year.

Why the margin moved: operating margin went +15.7 pp year on year while gross margin went +4.6 pp — the gain came mostly below the gross line: operating leverage, with costs spread over a bigger revenue base.

Worth repeating from the valuation section: cheap against its own history on record margins is not the same thing as cheap — a record margin flatters every ratio built on top of it.

→ Margins held — did that reach the bottom line? Next: profit null in the latest quarter.

Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.

BeOne Medicines AG earned $0.2 B of net profit in the Mar 26 quarter. Full-year FY25 profit was $0.3 B. That is 15.2% of the quarter's revenue. The same quarter a year earlier earned $0.0 B. 6 of the last 12 reported quarters were loss-making.

BeOne Medicines AG earned $0.2 B of net profit in the Mar 26 quarter. Full-year FY25 profit was $0.3 B. That is 15.2% of the quarter's revenue. The same quarter a year earlier earned $0.0 B. 6 of the last 12 reported quarters were loss-making.

Mar 26 profit was $0.2 B, null year on year. On the full year, FY25 printed $0.3 B (null).

→ Profit rose — but did the cash follow?

Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.

BeOne Medicines AG's cash-flow history is too thin to judge how much reported profit converts into cash. In FY25 that was $1.1 B of operating cash against $0.3 B of profit. After $0.2 B of capital spending, $0.9 B was left as free cash. Cash resolution here is annual, because quarterly cash statements are not published.

FY25: operating cash of $1.1 B against reported profit of $0.3 B, leaving free cash of $0.9 B after $0.2 B of capital spending.

Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.

Router verdict: the visible cash user is investment — the next section checks what the spending is buying.

→ So follow the cash to where it goes. Next: $1.0 B of building over 3 years.

Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).

BeOne Medicines AG does not report the debtor, inventory and payable day-counts a cash cycle is built from, so this section reads the investment side instead. Capital spending ran $1.0 B over the last 3 years. Averaged over those years that is 6.2% of FY25 revenue a year.

Working-capital day-counts are not in our numbers for this stock, so this section reads the investment side — where the cash is being put to work.

On the investment side: capital spending of $1.0 B over the last 3 fiscal years.

The synthesis: the cash is going into capacity, not disappearing into the cycle — the question becomes whether the new capacity earns.

→ Does all this activity actually earn its cost of capital? Next: ROE is 12% and the ROIC − WACC spread is +21.2 pp.

Return on equity Return on equity (ROE) is the profit the business earns on its shareholders’ money. With the full capital-employed split not in our numbers, ROE is the cleanest long ladder we can draw here.

BeOne Medicines AG earns a ROE of 7% in FY25. That is up from a trough of −46% in FY22. Return on invested capital clears the cost of that capital by +21.2 percentage points, so growth here adds value rather than only size. The wiring behind it is 5.4% net margin on 0.65× asset turns.

FY25 ROE is 7%, recovered from a FY22 trough of −46% — the full ladder below shows the fall and the climb, undoctored.

Why the return is what it is — the wiring (FY25): 5.4% net margin × 0.65× asset turns × 1.88× balance-sheet leverage ≈ 6.6% on equity. Margin does its share; leverage is a meaningful part of the equation.

The capstone test — ROIC − WACC: 28.0% − 6.8% = a +21.2 pp spread. The 6.8% is an estimate of this company's own cost of capital — read the sign and the size of the spread, not the decimals. A spread this wide means every dollar reinvested creates more than a dollar of value — the engine compounds.

→ Returns like these — is the balance sheet borrowing to make them? Next: debt-to-equity is 0.43.

Dividend

BeOne Medicines AG pays no dividend. Across the last 12 reported quarters it has declared no dividend per share, so there is no payout history to chart and no yield to quote. Companies at this stage typically reinvest earnings rather than distribute them, which makes the cash-flow and reinvestment sections the place that cash shows up.

BeOne Medicines AG does not currently pay a dividend. Across the last 12 reported quarters the company has declared no dividend per share, so there is no payout history to chart and no yield to quote. Companies at this stage typically reinvest earnings instead of distributing them.

→ No payout to follow. The cash question becomes what the business does with what it earns instead.

Debt Debt-to-equity says how much of the business is funded by borrowings. Low is the safe corner; the trend matters as much as the level.

BeOne Medicines AG carries total debt of $2.0 B against shareholder equity of $4.8 B as of Mar 26, a debt-to-equity of 0.43. On the annual view that ratio went from 0.11 in FY21 to 0.46 in FY25. Read the returns elsewhere on this page with that leverage in mind.

Mar 26: total debt of $2.0 B against shareholder equity of $4.8 B — a debt-to-equity of 0.43. On the annual view, debt-to-equity went from 0.11 (FY21) to 0.46 (FY25). Read the returns on this page with that leverage in mind.

→ Who owns this, and are they adding or leaving? Next: the register.

Ownership There is no quarter-by-quarter holder register to read here, so we read the crowd through short interest — the slice of tradable shares currently sold short, positioned for a fall.

No ownership or positioning reading is held for BeOne Medicines AG, so this section names the gap rather than filling it. At typical trading volumes those positions would take about 2.8 days to buy back. There is no quarter-by-quarter holder register to read for this filer, so the crowd is read through short interest instead.

We hold no ownership or positioning reading for this stock, so this section says that plainly.

→ One last check: does the safety math agree? Next: the balance-sheet safety line.

Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.

BeOne Medicines AG: the Z-score reads 5.51. A Z-score above roughly 3 reads as safe and below roughly 1.8 as the distress zone, so this sits well clear of distress. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure.

Why it matters: a Z-score of 5.51 sits well clear of the distress zone — the balance sheet is not the risk here.

The safety line in one sentence: the Z-score reads 5.51.

Frequently asked questions